-

Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers

Instrument verifies through both transparent and non-transparent packaging

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a handheld instrument that accelerates quality control testing in the pharmaceutical and biopharmaceutical industries.

Vaya verifies raw material identity through unopened transparent and non-transparent packaging, testing more containers for the same cost by reducing the need for sampling. Incoming goods can be tested quickly in the warehouse on receipt, reducing operator time and sample-handling booth usage. Testing through sealed containers also avoids handler exposure to high potency APIs and maintains the shelf life of sterile contents, helping to prevent unnecessary waste.

“Improving the speed and efficiency of raw material testing has a major impact on pharma and biopharma manufacturing,” said Paul Loeffen, Agilent vice president and general manager of the company’s Molecular Spectroscopy Division. “Testing requirements are trending toward higher volumes, even 100% of containers in many cases, and conventional techniques can be extremely resource-intensive. Vaya’s through-container capability bypasses the bottlenecks, offering our customers a significant cost- and resource-saving solution.”

Vaya is the first true through-barrier handheld Raman instrument, incorporating Agilent’s spatially offset Raman spectroscopy (SORS) technology for fast ID of incoming goods through opaque containers in a GMP ready package. Vaya combines SORS with conventional Raman spectroscopy for maximum compatibility with a wide range of packaging–from clear glass vials and plastic bags to opaque plastics and paper sacks.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

More News From Agilent Technologies Inc.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...
Back to Newsroom